Powered by: Motilal Oswal

News

Neutral Biocon Ltd For Target Rs.300 By Motilal Oswal Financial Services Ltd ‘VAI’ brings much-needed regulatory respite Await clarity on Malaysia inspection * Biocon (BIOS) has received ‘voluntary action indicated’ (VAI) for its Biocon Park, Bengaluru. The approvals for these sites were stuck for more than 15 months. * A favorable compliance outcome provides visibility for product approvals, namely b-Bevacizumab and b-Ustekinumab. Further, the VAI classification for this park provides a boost to the Liraglutide opportunity as well. ...
Neutral Biocon Ltd For Target Rs.300 By Motilal Oswal Financial Services Ltd
Neutral Biocon Ltd For Target Rs.300 By Motilal Oswal Financial Services Ltd
Source: Motilal Oswal Financial Services
2024-12-01 10:29:51 am
Accumulate Biocon Ltd For Target Rs.376 By Geojit Financial Services Ltd Increasing Demand, Positive Outlook Biocon Ltd is a biopharmaceutical company that develops therapies for chronic diseases such as autoimmune, cancer and diabetes. The company has developed and introduced novel biologics, biosimilars, differentiated small molecules and affordable recombinant human insulin and analogues. * In Q2FY25, Biocon's consolidated revenue grew 3.7% YoY to Rs. 3,590cr, primarily driven by strong sales in the biosimilar segment. * Biosimilar segment saw a 10...
Accumulate Biocon Ltd For Target Rs.376 By Geojit Financial Services Ltd
Accumulate Biocon Ltd For Target Rs.376 By Geojit Financial Services Ltd
Source: Geojit Financial Services Ltd
2024-11-24 02:10:24 pm
Neutral Biocon Ltd For Target Rs.300 By Motilal Oswal Financial Services Ltd Generic/currency headwinds in biologics drag down earnings * Currency headwinds in the biologics segment, pricing challenges, and a planned shutdown in the generics segment affected the overall performance of BIOS in 2QFY25. *  Despite these challenges, BIOS delivered improved profitability QoQ thanks to a strong revival in its Syngene business. It also continued to gain decent market share by volume in its key biosimilars in the US and EU. New launches, including liraglutide ...
Neutral Biocon Ltd For Target Rs.300 By Motilal Oswal Financial Services Ltd
Neutral Biocon Ltd For Target Rs.300 By Motilal Oswal Financial Services Ltd
Source: Motilal Oswal Financial Services Ltd
2024-11-15 12:17:54 pm
Biocon trades lower on reporting 84% fall in Q2 consolidated net profit Biocon is currently trading at Rs. 307.50, down by 10.40 points or 3.27% from its previous closing of Rs. 317.90 on the BSE. The scrip opened at Rs. 317.05 and has touched a high and low of Rs. 317.05 and Rs. 307.50 respectively. So far 43440 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 395.65 on 17-Sep-2024 and a 52 week low of Rs. 222.55 on 10-Nov-2023. Last one week high and low of the scrip stood at Rs. 3...
Biocon trades lower on reporting 84% fall in Q2 consolidated net profit
Biocon trades lower on reporting 84% fall in Q2 consolidated net profit
Source: Accord Fintech
2024-11-04 10:29:28 am
Biocon falls after USFDA completes surveillance inspection at its API facility with four observations Biocon is currently trading at Rs. 363.55, down by 5.15 points or 1.40% from its previous closing of Rs. 368.70 on the BSE. The scrip opened at Rs. 366.85 and has touched a high and low of Rs. 369.00 and Rs. 361.50 respectively. So far 151349 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 395.65 on 17-Sep-2024 and a 52 week low of Rs. 217.50 on 31-Oct-2023. Last one week high and low of the scrip stood at Rs. 3...
Biocon falls after USFDA completes surveillance inspection at its API facility with four observations
Biocon falls after USFDA completes surveillance inspection at its API facility with four observations
Source: Accord Fintech
2024-09-30 02:51:32 pm
Biocon moves up on inking pact with Tabuk Pharmaceutical Manufacturing Company Biocon is currently trading at Rs. 374.15, up by 1.65 points or 0.44% from its previous closing of Rs. 372.50 on the BSE. The scrip opened at Rs. 376.35 and has touched a high and low of Rs. 378.60 and Rs. 373.90 respectively. So far 36893 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 395.65 on 17-Sep-2024 and a 52 week low of Rs. 217.50 on 31-Oct-2023. Last one week high and low of the scrip stood at Rs. 381....
Biocon moves up on inking pact with Tabuk Pharmaceutical Manufacturing Company
Biocon moves up on inking pact with Tabuk Pharmaceutical Manufacturing Company
Source: Accord Fintech
2024-09-27 09:53:13 am
Stock Picks : Biocon Ltd And Hindalco Ltd By ICICI Direct Biocon Ltd Buy Biocon Ltd @ 390.50-391.50 Target 395.80 Stop Loss 388.20   Hindalco Ltd  Buy Hindalco Ltd @ 685-686 Target 693.00 Stop Loss 681.40   Please refer disclaimer at https://secure.icicidirect.com/Content/StaticData/Disclaimer.html SEBI Registration number INZ000183631
Stock Picks : Biocon Ltd And Hindalco Ltd By ICICI Direct
Stock Picks : Biocon Ltd And Hindalco Ltd By ICICI Direct
Source: ICICI Direct
2024-09-17 10:47:25 am
Stock Picks : Biocon Ltd And Havells India Ltd By ICICI Direct Biocon Ltd Buy Biocon Ltd @ 384-386 Target 390.20 Stop Loss 382.80   Havells India Ltd Buy Havells India Ltd @ 1921-1923 Target 1943.00 Stop Loss 1909.70   Please refer disclaimer at https://secure.icicidirect.com/Content/StaticData/Disclaimer.html SEBI Registration number INZ000183631
Stock Picks : Biocon Ltd And Havells India Ltd By ICICI Direct
Stock Picks : Biocon Ltd And Havells India Ltd By ICICI Direct
Source: ICICI Direct
2024-09-11 10:32:58 am
Stock Picks : Biocon Ltd And Dabur India Ltd By ICICI Direct Biocon Ltd Buy Biocon Ltd @ 377-378 Target 382.00 Stop Loss 374.40   Dabur India Ltd Buy Dabur India Ltd @ 658-660 Target 666.20 Stop Loss 655.80   Please refer disclaimer at https://secure.icicidirect.com/Content/StaticData/Disclaimer.html SEBI Registration number INZ000183631
Stock Picks : Biocon Ltd And Dabur India Ltd By ICICI Direct
Stock Picks : Biocon Ltd And Dabur India Ltd By ICICI Direct
Source: ICICI Direct
2024-09-10 10:43:35 am
Stock Picks : Dabur Ltd And Biocon Ltd By ICICI Direct Dabur Ltd Buy Dabur Ltd @ 648-650 Target 656.00 Stop Loss 645.40   Biocon Ltd Buy Biocon Ltd @ 375-377 Target 381.20 Stop Loss 373.40   Please refer disclaimer at https://secure.icicidirect.com/Content/StaticData/Disclaimer.html SEBI Registration number INZ000183631
Stock Picks : Dabur Ltd And Biocon Ltd By ICICI Direct
Stock Picks : Dabur Ltd And Biocon Ltd By ICICI Direct
Source: ICICI Direct
2024-09-05 10:35:57 am
Stock of the day : Biocon Ltd For Target Rs. 400 - Religare Broking Biocon Ltd  * We are seeing a noticeable resilience in the pharma pack and BIOCON is leading from the front. * The stock has registered a breakout from a bullish rectangle pattern with strong surge in volumes. * The chart pattern and uptick in volumes denotes price to attract fresh upward momentum. * Hence, traders can consider longs in the mentioned range Buy Biocon Ltd CMP 379.4 Range 378-380 SL 366 Target 400   ...
Stock of the day : Biocon Ltd For Target Rs. 400 - Religare Broking
Stock of the day : Biocon Ltd For Target Rs. 400 - Religare Broking
Source: Religare Broking Ltd
2024-09-05 10:27:19 am
Biocon rises as its arm secures approval from USFDA for Sacubitril/Valsartan Tablets Biocon is currently trading at Rs. 361.45, up by 2.15 points or 0.60% from its previous closing of Rs. 359.30 on the BSE. The scrip opened at Rs. 367.50 and has touched a high and low of Rs. 368.00 and Rs. 359.00 respectively. So far 130805 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 376.75 on 26-Jul-2024 and a 52 week low of Rs. 217.50 on 31-Oct-2023. Last one week high and low of the scrip stood at Rs. 368...
Biocon rises as its arm secures approval from USFDA for Sacubitril/Valsartan Tablets
Biocon rises as its arm secures approval from USFDA for Sacubitril/Valsartan Tablets
Source: Accord Fintech
2024-09-02 11:18:40 am
Neutral Biocon Ltd. For Target Rs. 280 - Motilal Oswal Financial Services Biosimilar off-take, lower R&D spending drive earnings Work-in-progress to improve business outlook across segments *  Biocon (BIOS) delivered better-than-expected adjusted earnings in 4QFY24, led by improved biosimilar sales and lower R&D spending. While EBITDA maintained its uptrend in FY24 and grew to INR29.4b, adj. PAT hit a 10-year low of INR2.6b, largely due to increased financial leverage and higher depreciation. *  We cut our earnings estimates by 19%/12% ...
Neutral Biocon Ltd. For Target Rs. 280 - Motilal Oswal Financial Services
Neutral Biocon Ltd. For Target Rs. 280 - Motilal Oswal Financial Services
Source: Motilal Oswal Financial Services
2024-06-30 03:15:54 pm
Stock Picks : WIPRO Ltd And Biocon Ltd By ICICI Direct WIPRO Ltd Sell WIPRO Ltd @450-451 Target 445.00 Stop Loss 453.70   Biocon Ltd Buy Biocon Ltd @319-320 Target 324.00 Stop Loss 317.70     Please refer disclaimer at https://secure.icicidirect.com/Content/StaticData/Disclaimer.html SEBI Registration number INZ000183631
Stock Picks : WIPRO Ltd And Biocon Ltd By ICICI Direct
Stock Picks : WIPRO Ltd And Biocon Ltd By ICICI Direct
Source: ICICI Direct
2024-05-30 10:44:31 am
Biocon soars on signing exclusive licensing, supply agreement with Handok Biocon is currently trading at Rs. 325.65, up by 10.30 points or 3.27% from its previous closing of Rs. 315.35 on the BSE. The scrip opened at Rs. 318.70 and has touched a high and low of Rs. 326.85 and Rs. 317.30 respectively. So far 69025 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 326.85 on 24-May-2024 and a 52 week low of Rs. 217.50 on 31-Oct-2023. Last one week high and low of the scrip stood at Rs. 326...
Biocon soars on signing exclusive licensing, supply agreement with Handok
Biocon soars on signing exclusive licensing, supply agreement with Handok
Source: Accord Fintech
2024-05-24 09:54:38 am
Biocon rises as its arm gets USFDA`s nod for Yesafili Biocon is currently trading at Rs. 306.40, up by 1.70 points or 0.56% from its previous closing of Rs. 304.70 on the BSE. The scrip opened at Rs. 307.80 and has touched a high and low of Rs. 310.35 and Rs. 304.10 respectively. So far 93310 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 321.30 on 15-May-2024 and a 52 week low of Rs. 217.50 on 31-Oct-2023. Last one week high and low of the scrip stood at Rs. 321....
Biocon rises as its arm gets USFDA`s nod for Yesafili
Biocon rises as its arm gets USFDA`s nod for Yesafili
Source: Accord Fintech
2024-05-21 10:49:46 am
India's Biocon developing its own version of Wegovy, clinical trial likely next year Indian drugmaker Biocon, looking to grab a piece of the exploding weight-loss drug market as early as possible, is developing its own version of Novo Nordisk's wildly popular Wegovy and is prepared to conduct a clinical trial next year if needed, the CEO told Reuters. Wall Street has forecast the market for this new generation of obesity treatments reaching at least $100 billion by the end of the decade, and Biocon is taking steps to be a part of that windfall. "We're going...
India's Biocon developing its own version of Wegovy, clinical trial likely next year
India's Biocon developing its own version of Wegovy, clinical trial likely next year
Source: Reuters
2024-04-19 10:09:40 am
Biocon shines on signing licensing and supply agreement with Biomm S.A. Biocon is currently trading at Rs. 270.20, up by 7.10 points or 2.70% from its previous closing of Rs. 263.10 on the BSE. The scrip opened at Rs. 272.25 and has touched a high and low of Rs. 273.00 and Rs. 269.85 respectively. So far 38099 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 307.00 on 06-Feb-2024 and a 52 week low of Rs. 217.50 on 31-Oct-2023. Last one week high and low of the scrip stood at Rs. 282....
Biocon shines on signing licensing and supply agreement with Biomm S.A.
Biocon shines on signing licensing and supply agreement with Biomm S.A.
Source: Accord Fintech
2024-04-18 10:37:47 am
Biocon shines on getting approval from MHRA, UK for complex formulation Liraglutide Biocon is currently trading at Rs. 260.55, up by 3.95 points or 1.54% from its previous closing of Rs. 256.60 on the BSE. The scrip opened at Rs. 257.55 and has touched a high and low of Rs. 263.30 and Rs. 257.55 respectively. So far 65422 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 307.00 on 06-Feb-2024 and a 52 week low of Rs. 199.30 on 29-Mar-2023. Last one week high and low of the scrip stood at Rs. 263....
Biocon shines on getting approval from MHRA, UK for complex formulation Liraglutide
Biocon shines on getting approval from MHRA, UK for complex formulation Liraglutide
Source: Accord Fintech
2024-03-28 10:14:03 am
India`s Biocon to sell branded formulations business to Eris Lifesciences for $150 million Biopharmaceutical company Biocon's unit Biocon Biologics will sell its Indian branded formulations businesses to Eris Lifesciences in a deal worth 12.42 billion rupees ($150 million), the companies said in separate exchange filings on Thursday. The deal, which is expected to close by April 15, 2024, includes the acquisition of insulin brands Basalog and Insugen which Eris said will help its diabetes treatment franchise reach 10 billion rupees in revenue, without specifying a timeline. ...
India`s Biocon to sell branded formulations business to Eris Lifesciences for $150 million
India`s Biocon to sell branded formulations business to Eris Lifesciences for $150 million
Source: Reuters
2024-03-14 04:45:28 pm
India`s Biocon posts profit on biosimilar boost, divestment gains; CFO resigns  Indian biopharmaceutical company Biocon Ltd swung to a third-quarter profit on Thursday, boosted by its biosimilars business and the sale of some of its non-core units, and said Chief Financial Officer Indranil Sen had resigned. Sen, who has been with the company for nearly a decade, resigned from the role to pursue career opportunities outside of Biocon, it said. He will be with the company until March 15. For the latest quarter, the Bengaluru-based company reported a consolidate...
India`s Biocon posts profit on biosimilar boost, divestment gains; CFO resigns
India`s Biocon posts profit on biosimilar boost, divestment gains; CFO resigns
Source: Reuters
2024-02-09 09:48:52 am
Stock Picks : Biocon Ltd And DLF Ltd By ICICI Direct Biocon Ltd Buy Biocon Ltd @282-283; Target 288.00; Stop Loss 3734.00   DLF Ltd Sell DLF Ltd @778-780; Target 768.00; Stop Loss 786.00   Please refer disclaimer at https://secure.icicidirect.com/Content/StaticData/Disclaimer.html SEBI Registration number INZ000183631
Stock Picks : Biocon Ltd And DLF Ltd By ICICI Direct
Stock Picks : Biocon Ltd And DLF Ltd By ICICI Direct
Source: ICICI Direct
2024-01-17 09:57:02 am
Stock Picks : Hindustan Unilever Ltd And Biocon Ltd By ICICI Direct Hindustan Unilever Ltd   Buy Hindustan Unilever Ltd @2651-2653; Target 2679.00; Stop Loss 2638.00   Biocon Ltd Buy Biocon Ltd @254-255; Target 258.00; Stop Loss 252.80   Please refer disclaimer at https://secure.icicidirect.com/Content/StaticData/Disclaimer.html SEBI Registration number INZ000183631  
Stock Picks : Hindustan Unilever Ltd And Biocon Ltd By ICICI Direct
Stock Picks : Hindustan Unilever Ltd And Biocon Ltd By ICICI Direct
Source: ICICI Direct
2024-01-02 10:55:30 am
Neutral Biocon Ltd For Target Rs. 220 - Motilal Oswal Financial Services Ltd Enhanced efforts needed to improve biosimilars outlook * Biocon (BIOS) has delivered 22%/25% revenue/EBITDA CAGR over FY18-23, led by robust traction in biosimilars and research services. However, earnings CAGR have been lower at 15% over FY18-23 due to increased financial leverage and depreciation. * While BIOS continues to work on enhancing its biosimilar (49% of FY23 sales) pipeline and expand the reach of commercialized products, regulatory issues at its sites may prolong the approv...
Neutral Biocon Ltd For Target Rs. 220 - Motilal Oswal Financial Services Ltd
Neutral Biocon Ltd For Target Rs. 220 - Motilal Oswal Financial Services Ltd
Source: Motilal Oswal Financial Services Ltd
2023-12-12 02:38:49 pm
Buy Biocon Ltd For Target Rs.340 - JM Financial Institutional Securities BIOS’ 2Q earnings was below JMFe. Generics performance was lower due to API pricing pressure and planned shutdown; meanwhile, lower licensing income QoQ led to BBL miss. The 2024 inclusions for Fulphila/ Ogivri by a large payor, two payor additions for Semglee and unbranded Humira addition by CVS are indeed the key positive readouts. bHumira’s slow ramp-up has been apparent and Aspart delay is in the price. However, Syngene’s guidance cut was the key negative development. Ov...
Buy Biocon Ltd For Target Rs.340 - JM Financial Institutional Securities
Buy Biocon Ltd For Target Rs.340 - JM Financial Institutional Securities
Source: JM Financial Institutional Securities Ltd
2023-12-07 04:32:09 pm
Bengaluru Tech Summit 2023 an `unprecedented success`: Karnataka Minister Priyank Kharge Karnataka Minister for Information Technology and Biotechnology, Priyank Kharge, said that the three-day Bengaluru Tech Summit 2023, held at the Bangalore Palace, concluded with unprecedented and resounding success, breaking new ground in the realm of technology and innovation. Speaking to mediapersons, Kharge added that the Bengaluru Tech Summit 2023 has been a global standout, with participants from 45 countries, 83 sessions and insights from 401 speakers. The event themed "Break...
Bengaluru Tech Summit 2023 an `unprecedented success`: Karnataka Minister Priyank Kharge
Bengaluru Tech Summit 2023 an `unprecedented success`: Karnataka Minister Priyank Kharge
Source: IANS
2023-12-02 08:54:26 am
India's Biocon misses Q2 profit view on higher expenses Indian biopharmaceutical company Biocon reported a smaller-than-expected quarterly profit on Friday hurt by higher expenses. The company's consolidated net profit rose to 1.26 billion rupees ($15.13 million) for the quarter ended Sept. 30 from 469 million rupees a year earlier. Analysts, however, had expected a profit of 1.77 billion rupees, according to LSEG data. Total expenses surged 59% to 33.58 billion rupees, the company said. Biocon also increased spending on research and ...
India's Biocon misses Q2 profit view on higher expenses
India's Biocon misses Q2 profit view on higher expenses
Source: Reuters
2023-11-12 08:53:38 am
Biocon`s net profit doubles to Rs 172.7 crore in Q2 Indian pharmaceutical giant Biocon on Friday reported a net profit of Rs 172.7 crore in the September quarter of financial year 2023-24, more than double its profit of Rs 81.8 crore in the same period of the previous year. According to the company statement, the company’s revenue increased by 52 per cent YoY to Rs 3,462.3 crore in the quarter. Biocon and Biocon Biologics Biocon Executive Chairperson Kiran Mazumdar-Shaw said: "Biocon reported a strong revenue growth this quart...
Biocon`s net profit doubles to Rs 172.7 crore in Q2
Biocon`s net profit doubles to Rs 172.7 crore in Q2
Source: IANS
2023-11-11 09:30:13 am
Nifty closed in the green on 5 occasions in month of November for last 10 yrs An analysis for the month of November indicated that the Nifty had closed in the green on five occasions with an average return of 1.2 per cent in the last 10 years, JM Financial Institutional Securities said in a report.The Nifty Mid-cap index, on the other hand, has shown a relatively stronger seasonality, closing in the green on eight occasions with an average return of 2.1 per cent, the report said.It has managed to outperform the Nifty on seven occasions with an average outperformance of...
Nifty closed in the green on 5 occasions in month of November for last 10 yrs
Nifty closed in the green on 5 occasions in month of November for last 10 yrs
Source: IANS
2023-10-26 01:52:06 pm
Kedar Upadhye appointed new CFO of Biocon Biologics Kedar Upadhye has been appointed as the new Chief Financial Officer (CFO) of Biocon Biologics while current CFO, M.B. Chinappa will take on a strategic finance role at Biocon Group. These leadership changes will be effective October 31, stated an official release on Thursday.M.B. Chinappa has served as CFO of Biocon Biologics since his appointment in January 2020 and has played an integral role in developing business strategy and enabling profitable growth. He has helped secure over $500 mill...
Kedar Upadhye appointed new CFO of Biocon Biologics
Kedar Upadhye appointed new CFO of Biocon Biologics
Source: IANS
2023-10-20 09:25:15 am
Buy Biocon Ltd For Target Rs. 370 - JM Financial Institutional Securities BIOS? implied hold co discount is now >40% - this makes the risk-reward extremely favourable. As key triggers play out over the next few quarters, BIOS? stock price can significantly re-rate, in our view. Near-term drivers for the stock are: (1) bAspart and bBeva approval/ launch; (2) Formulary access for Hulio; and (3) A positive outcome for bAflibercept. The delay in approvals and a highly leveraged acquisition have admittedly spooked the street, but BIOS is relatively well-placed t...
Buy Biocon Ltd For Target Rs. 370 - JM Financial Institutional Securities
Buy Biocon Ltd For Target Rs. 370 - JM Financial Institutional Securities
Source: JM Financial Institutional Securities Ltd
2023-10-04 03:34:56 pm
India`s Biocon names Peter Bains as group CEO Indian drugmaker Biocon Ltd on Monday appointed Peter Bains as the group's chief executive officer, effective immediately.Bains, who was named as an independent director of the Biocon board in December last year, stepped down on Monday to assume the top charge, the company said in a statement."Peter has a unique fit and profile for the role having ... a comprehensive understanding of the Biocon Group ... having led Syngene for five years, (and) taking it through its very successful IPO in 201...
India`s Biocon names Peter Bains as group CEO
India`s Biocon names Peter Bains as group CEO
Source: Reuters
2023-09-19 11:29:43am